Durand E
Unité de Consultations et de Soins Ambulatoires des Maisons d'Arrêt de Fleury-Mérogis, 7, avenue des Peupliers, 91705 Sainte-Geneviève-des-Bois, France.
Ann Med Interne (Paris). 2001 Nov;152 Suppl 7:9-14.
Since the law of January 1994, the ministry of Health is responsible for inmate health in France. This law created medical wards inside French prisons by conventions between hospitals and prisons. Since July 1995, Fleury-Merogis state-prison is linked to the Sud-Francilien Hospital. During the last few years, more and more IV drug users have been incarcerated and the number of infectious diseases has increased (AIDS, hepatitis C and B). Risk behavior is rather frequent and it has become a major concern of public authorities to fight this evolution. Prisons are part of structures having to take care of IV drug users. A few months after the authorization of buprenorphine in France (March 1996), the ministry of Health decided to give access to this treatment for incarcerated IV drug users. The aim of this study is to present the evolution of maintenance medication by high dose buprenorphine in a big state-prison and to explain the difficulties we have to face. The aim of this study was also to present how this treatment can contribute to reducing infectious risks. Surveying prescription is under the control of the Pharmacy since 1995. We have studied since 1996 the number of prescriptions, segregating initialized inside the prison and prescriptions continued. We have also studied and evaluated the number of psychotropic drugs for each prescription since 1996 in "two test buildings". Evolution of self mutilations and reducing infectious risks support measures have also been studied.
自1994年1月的法律颁布以来,法国卫生部负责囚犯的健康。该法律通过医院与监狱之间的协议在法国监狱内设立了医疗病房。自1995年7月起,弗勒里-梅罗吉斯国家监狱与南法兰西医院建立了联系。在过去几年里,越来越多的静脉注射吸毒者被监禁,传染病数量有所增加(艾滋病、丙型和乙型肝炎)。危险行为相当普遍,应对这种变化已成为公共当局的主要关切。监狱是必须照顾静脉注射吸毒者的机构之一。在法国批准丁丙诺啡(1996年3月)几个月后,卫生部决定让被监禁的静脉注射吸毒者能够获得这种治疗。本研究的目的是介绍在一所大型国家监狱中高剂量丁丙诺啡维持治疗的演变情况,并说明我们必须面对的困难。本研究的目的还包括介绍这种治疗如何有助于降低感染风险。自1995年以来,处方调查由药房负责。自1996年以来,我们研究了监狱内新开处方和续开处方的数量。自1996年以来,我们还在“两栋试验楼”中研究并评估了每张处方中精神药物的数量。自残行为的演变以及降低感染风险的支持措施也得到了研究。